These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

92 related items for PubMed ID: 22182654

  • 1. Comments on Novel Therapy to Reverse the Cellular Effects of Bisphosphonates on Primary Human Oral Fibroblasts by Cozin M et al (2011).
    Ziebart T, Walter C.
    J Oral Maxillofac Surg; 2012 Jan; 70(1):3. PubMed ID: 22182654
    [No Abstract] [Full Text] [Related]

  • 2. Novel therapy to reverse the cellular effects of bisphosphonates on primary human oral fibroblasts.
    Cozin M, Pinker BM, Solemani K, Zuniga JM, Dadaian SC, Cremers S, Landesberg R, Raghavan S.
    J Oral Maxillofac Surg; 2011 Oct; 69(10):2564-78. PubMed ID: 21807448
    [Abstract] [Full Text] [Related]

  • 3. Oral bisphosphonates and bon.
    Fugazzotto PA, Lightfoot S.
    J Am Dent Assoc; 2006 Nov; 137(11):1504, 1506; author reply 1506, 1508. PubMed ID: 17082272
    [No Abstract] [Full Text] [Related]

  • 4. Zoledronic acid and geranylgeraniol regulate cellular behaviour and angiogenic gene expression in human gingival fibroblasts.
    Zafar S, Coates DE, Cullinan MP, Drummond BK, Milne T, Seymour GJ.
    J Oral Pathol Med; 2014 Oct; 43(9):711-21. PubMed ID: 24762323
    [Abstract] [Full Text] [Related]

  • 5. Effect of long-term oral bisphosphonates on implant wound healing: literature review and a case report.
    Wang HL, Weber D, McCauley LK.
    J Periodontol; 2007 Mar; 78(3):584-94. PubMed ID: 17335384
    [Abstract] [Full Text] [Related]

  • 6. Comments on ''Geranylgeraniol--a new potential therapeutic approach to bisphosphonate associated osteonecrosis of the jaw" by Ziebart T et al. (2011).
    Marcuzzi A, Zanin V, Crovella S, Pontillo A.
    Oral Oncol; 2011 May; 47(5):436-7; author reply 438. PubMed ID: 21411362
    [No Abstract] [Full Text] [Related]

  • 7. The effects of platelet-derived growth factor-BB on periodontal cells in an in vitro wound model.
    Mumford JH, Carnes DL, Cochran DL, Oates TW.
    J Periodontol; 2001 Mar; 72(3):331-40. PubMed ID: 11327060
    [Abstract] [Full Text] [Related]

  • 8. Zoledronic acid impairs re-epithelialization through down-regulation of integrin αvβ6 and transforming growth factor beta signalling in a three-dimensional in vitro wound healing model.
    Saito T, Izumi K, Shiomi A, Uenoyama A, Ohnuki H, Kato H, Terada M, Nozawa-Inoue K, Kawano Y, Takagi R, Maeda T.
    Int J Oral Maxillofac Surg; 2014 Mar; 43(3):373-80. PubMed ID: 24021731
    [Abstract] [Full Text] [Related]

  • 9. PRGF exerts a cytoprotective role in zoledronic acid-treated oral cells.
    Anitua E, Zalduendo M, Troya M, Orive G.
    Clin Oral Investig; 2016 Apr; 20(3):513-21. PubMed ID: 26201455
    [Abstract] [Full Text] [Related]

  • 10. Platelet-derived growth factor-BB stimulated cell migration mediated through p38 signal transduction pathway in periodontal cells.
    Ray AK, Jones AC, Carnes DL, Cochran DL, Mellonig JT, Oates TW.
    J Periodontol; 2003 Sep; 74(9):1320-8. PubMed ID: 14584865
    [Abstract] [Full Text] [Related]

  • 11. Intravenous bisphosphonates in osteoporosis and jaw osteonecrosis: comment on the article by Delmas et al.
    Landis BN, Hugentobler M.
    Arthritis Rheum; 2006 Nov; 54(11):3720-1; author reply 3721-2. PubMed ID: 17075888
    [No Abstract] [Full Text] [Related]

  • 12. Bisphosphonates and the dental practitioner--a guide to management.
    Williamson R.
    Ann R Australas Coll Dent Surg; 2010 Mar; 20():46-9. PubMed ID: 22046734
    [Abstract] [Full Text] [Related]

  • 13. Warning: bisphosphonates and osteochemonecrosis of the jaws.
    Flint SR, Sharkey S, Galvin S.
    J Ir Dent Assoc; 2006 Mar; 52(2):79-83. PubMed ID: 16989369
    [Abstract] [Full Text] [Related]

  • 14. Bisphosphonates and oral health.
    Ritter AV, Padilla R.
    J Esthet Restor Dent; 2008 Mar; 20(1):74-5. PubMed ID: 18237344
    [No Abstract] [Full Text] [Related]

  • 15. Residual (ghost) sockets in bisphosphonate use--evidence of poor healing and slow bone turnover.
    Shetty K, Bouquot J.
    Gen Dent; 2009 Mar; 57(2):130-5. PubMed ID: 19552362
    [Abstract] [Full Text] [Related]

  • 16. Oral bisphosphonates and oesophageal cancer.
    Wysowski DK.
    BMJ; 2010 Sep 01; 341():c4506. PubMed ID: 20813821
    [No Abstract] [Full Text] [Related]

  • 17. How do bisphosphonates affect fracture healing?
    Kates SL, Ackert-Bicknell CL.
    Injury; 2016 Jan 01; 47 Suppl 1(0 1):S65-8. PubMed ID: 26768295
    [Abstract] [Full Text] [Related]

  • 18. [Osteonecrosis of the jawbone as a side effect of intravenous treatment with bisphosphonates].
    Schortinghuis J, Witjes MJ, Spijkervet KL, de Visscher JG.
    Ned Tijdschr Geneeskd; 2007 Feb 03; 151(5):314-8. PubMed ID: 17326477
    [Abstract] [Full Text] [Related]

  • 19. Oral bisphosphonates and osteonecrosis of the jaw.
    Wynn RL.
    Gen Dent; 2007 Feb 03; 55(1):8-10. PubMed ID: 17333956
    [No Abstract] [Full Text] [Related]

  • 20. Re: implant placement with or without simultaneous tooth extraction in patients taking oral bisphosphonates: postoperative healing, early follow-up, and the incidence of complications in two private practices. Fugazzoto PA, Lightfoot WS, Jaffin R, Kumar A.(J Periodontol 2007; 78: 1664-1669).
    Elad S, Yarom N, Khamaisi M.
    J Periodontol; 2008 Apr 03; 79(4):584-5, author reply 585-6. PubMed ID: 18380548
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 5.